South korea developing covid 19 vaccine

 

The Ministry of Food and Drug Safety (Chief Lee Eui-kyung, South Korea, said that while the development of covid 19 treatments and vaccines is actively in progress around the world, it provides information on the status of clinical trials, permits, and examinations of treatments and vaccines being developed at home and abroad.

 

 

<Current status of approval for treatment and vaccine clinical trials>

□ A total of 13 clinical trials of therapeutics and vaccines currently in progress in South Korea related to covid 19 (11 treatments, 2 vaccines), and one domestically developed antibody treatment (CT-P59, 'since the announcement on July 10) 20.7.17. Approval) has been approved.

 

 

 

 

➊ covid 19 virus enters the respiratory system and causes infection.

➋ Plasma fractionation therapy or antibody therapy is given to the patient.

➌ Remove the covid 19 virus that has been invaded by the administered neutralizing antibody*.

   * Neutralizing antibodies: Antibodies that can neutralize (neutralize) the covid 19 virus

 

 

 

<Information on domestic and foreign plasma fractions>

□ Currently, plasma fraction therapy for covid 19 treatment is being developed at home and abroad.

 ○ ‘Plasma Fractional Treatment’ is a product that collects a large amount of plasma from the blood of a covid 19 curer and then concentrates thecovid 19 neutralizing antibody through several processes.

 ○ Currently, G company in Korea is developing a plasma fractionation treatment, and is in consultation with the Ministry of Food and Drug Safety to apply for a clinical trial plan.

 

-The Ministry of Food and Drug Safety has been developing and using a product that applies the same principle to treat diseases using neutralizing antibodies, as the raw material for plasma fractionation treatment is derived from the human body. Prizes were waived.

   -If a clinical trial is requested, the KFDA will review it quickly and approve the clinical trial plan if it is determined that safety is sufficiently secured.

 ○ Plasma fractionation treatment is based on the plasma of a cured person, so the production cost is not high, but it is difficult to mass-produce because there is no choice but to rely on blood donation.

   -Company G collected plasma of cured teeth and started producing clinical trial drugs from mid-July.

□ Overseas, five clinical trials for plasma fractionation are currently underway in France and Italy.

<Information on domestic and foreign antibody treatments>

□ Antibodies are being developed for corona19 treatment.

 ○'Antibody Therapeutics' is a mass production of antibodies by selecting the antibody that shows the strongest virus neutralization ability in the blood of a corona 19 cured and culturing the cells into which the antibody gene is inserted.

   -Antibody therapy has the advantage of being able to mass-produce and supply high-quality medicines stably regardless of the blood supply and demand of the cured person. However, a relatively high cost is put into production.

□ In Korea, C's antibody therapeutics have been approved for phase 1 clinical trials.

 ○ As a result of experiments with cells, antibody treatments of C were found to block viral infections. In animal experiments using weasels and hamsters, virus levels were lowered and inflammation was reduced.